BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 29076773)

  • 1. Targeting protein arginine methyltransferase 5 in disease.
    Richters A
    Future Med Chem; 2017 Nov; 9(17):2081-2098. PubMed ID: 29076773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein Arginine Methyltransferase 5 (PRMT5) as an Anticancer Target and Its Inhibitor Discovery.
    Wang Y; Hu W; Yuan Y
    J Med Chem; 2018 Nov; 61(21):9429-9441. PubMed ID: 29870258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting protein arginine methyltransferase 5 in cancers: Roles, inhibitors and mechanisms.
    Chen Y; Shao X; Zhao X; Ji Y; Liu X; Li P; Zhang M; Wang Q
    Biomed Pharmacother; 2021 Dec; 144():112252. PubMed ID: 34619493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of an AlphaLISA high throughput technique to screen for small molecule inhibitors targeting protein arginine methyltransferases.
    Prabhu L; Chen L; Wei H; Demir Ö; Safa A; Zeng L; Amaro RE; O'Neil BH; Zhang ZY; Lu T
    Mol Biosyst; 2017 Nov; 13(12):2509-2520. PubMed ID: 29099132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors.
    Zhu K; Song JL; Tao HR; Cheng ZQ; Jiang CS; Zhang H
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3693-3699. PubMed ID: 30366617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arginine methyltransferase inhibitor 1 inhibits gastric cancer by downregulating eIF4E and targeting PRMT5.
    Zhang B; Zhang S; Zhu L; Chen X; Zhao Y; Chao L; Zhou J; Wang X; Zhang X; Ma N
    Toxicol Appl Pharmacol; 2017 Dec; 336():1-7. PubMed ID: 28987382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.
    Ji S; Ma S; Wang WJ; Huang SZ; Wang TQ; Xiang R; Hu YG; Chen Q; Li LL; Yang SY
    Chem Biol Drug Des; 2017 Apr; 89(4):585-598. PubMed ID: 27714957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
    Fu S; Zheng Q; Zhang D; Lin C; Ouyang L; Zhang J; Chen L
    Eur J Med Chem; 2022 Dec; 244():114842. PubMed ID: 36274274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
    Sloan SL; Renaldo KA; Long M; Chung JH; Courtney LE; Shilo K; Youssef Y; Schlotter S; Brown F; Klamer BG; Zhang X; Yilmaz AS; Ozer HG; Valli VE; Vaddi K; Scherle P; Alinari L; Kisseberth WC; Baiocchi RA
    PLoS One; 2021; 16(5):e0250839. PubMed ID: 33989303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors.
    Lin H; Luengo JI
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1264-1269. PubMed ID: 30956011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein arginine methyltransferase 5: a potential cancer therapeutic target.
    Yuan Y; Nie H
    Cell Oncol (Dordr); 2021 Feb; 44(1):33-44. PubMed ID: 33469838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
    Zheng BN; Ding CH; Chen SJ; Zhu K; Shao J; Feng J; Xu WP; Cai LY; Zhu CP; Duan W; Ding J; Zhang X; Luo C; Xie WF
    Theranostics; 2019; 9(9):2606-2617. PubMed ID: 31131056
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of protein arginine methyltransferase 5 in human cancers.
    Xiao W; Chen X; Liu L; Shu Y; Zhang M; Zhong Y
    Biomed Pharmacother; 2019 Jun; 114():108790. PubMed ID: 30903920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3.
    Zhang B; Dong S; Zhu R; Hu C; Hou J; Li Y; Zhao Q; Shao X; Bu Q; Li H; Wu Y; Cen X; Zhao Y
    Oncotarget; 2015 Sep; 6(26):22799-811. PubMed ID: 26078354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational Design, synthesis and biological evaluation of novel triazole derivatives as potent and selective PRMT5 inhibitors with antitumor activity.
    Zhu K; Shao J; Tao H; Yan X; Luo C; Zhang H; Duan W
    J Comput Aided Mol Des; 2019 Aug; 33(8):775-785. PubMed ID: 31312965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond.
    Stopa N; Krebs JE; Shechter D
    Cell Mol Life Sci; 2015 Jun; 72(11):2041-59. PubMed ID: 25662273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Arginine Methyltransferase PRMT5 for Cancer Therapy: Updated Progress and Novel Strategies.
    Zheng J; Li B; Wu Y; Wu X; Wang Y
    J Med Chem; 2023 Jul; 66(13):8407-8427. PubMed ID: 37366223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic small molecule modulators of histone and DNA methylation.
    Hauser AT; Robaa D; Jung M
    Curr Opin Chem Biol; 2018 Aug; 45():73-85. PubMed ID: 29579619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein arginine N-methyltransferase 5 in colorectal carcinoma: Insights into mechanisms of pathogenesis and therapeutic strategies.
    Abumustafa W; Zamer BA; Khalil BA; Hamad M; Maghazachi AA; Muhammad JS
    Biomed Pharmacother; 2022 Jan; 145():112368. PubMed ID: 34794114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein arginine methyltransferase 5 catalyzes substrate dimethylation in a distributive fashion.
    Wang M; Fuhrmann J; Thompson PR
    Biochemistry; 2014 Dec; 53(50):7884-92. PubMed ID: 25485739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.